Tagged with R

biotech Biograft is the first private tissue bank in Mexico meeting the increasing demand for implants of human musculoskeletal tissue. The general director and founder discusses the vision behind the creation of Biograft, how the company mastered to overcome skepticism and the plans to expand exports and transform the company in…

manufacturing Merck is getting “Fit for 2018”. Pedro Galvis, the company’s managing director for Mexico, discusses how the company’s transformation program, implemented in 2012, is ensuring future growth and how Mexico’s manufacturing cost competitiveness has driven further investment in production capacities. What is the major challenge that R&D-driven multinational companies face…

clinical trials The general manager of a leading British research-based pharmaceutical company discusses Algeria’s suitability as a destination for pre-clinical and clinical trials and assesses the country’s ability to transition from importer to local producer status Can you please start by briefly introducing GSK in Algeria? GSK activities in Algeria span three…

pharmaceuticals The general manager of IMS Health Argentina – South Cone weighs in on why his organization plays a crucial role in the pharma industry in Argentina. How does the Argentinean market look today? The Argentinean market is a solid, mature and competitive business with a lot of potential in biotechnology…

pharmaceutical trade Dr. Valverde, a respected authority on pharmacovigilance from the University of Mamonides, discusses the emerging pharmaceutical trade relationship between China and Argentina in the context of the dynamic Argentinian industry. To begin, would you please introduce the Cámara Argentinos-China? The Argentinian Republic and the People’s Republic of China established trade…

biosimilar Laboratorios Elea’s General Manager tells the story of the laboratories outstanding growth over the previous five years, the his firms upcoming launch of the first Argentinian developed biosimilar product. To begin, would you please introduce yourself and Elea to our readers? I joined Elea four years ago as general manager,…

orphan drugs Aegerion’s representative in Argentina discusses her efforts to raise awareness of Homozygous Familial Hypercholesteremia (HoFH), the rare disease targeted by her company’s ultra-orphan drug, and the remaining challenges of diagnosing patients. What is the current state of affairs for HoFH patients in Argentina? So far, as lomitapide is not yet…

pricing Daniel Varde, Deloitte’s top consultant for the healthcare and life sciences sector in Latin America, discusses the interaction of global, Latin American, and Argentinian healthcare trends, and strategic techniques for optimizing a pharmaceutical firm’s performance in Argentina’s price-controlled, high inflation market. With the current inflationary pressures to reduce costs, why…

innovation Lee Han-Koo, president of Daehwa Pharmaceutical, explains his strategy to corner the transdermal drug delivery system (TDDS) market through innovative patch products as well as a special focus on oral anticancer medication. Could you briefly introduce our readers to Daehwa? Daehwa was founded in January 1984 and listed on the…

healthcare “Argentina’s health system is in agony” In March 2002, amidst an economic crisis and national healthcare emergency the then Minister of Health Gines Gonzales Garcia declared “Argentina’s health system is in agony… What is lacking is money, not drugs. Our country has the best pharmaceutical industry in Latin America. The…

diabetes treatment Novo Nordisk’s market access and public affairs director discusses the state of diabetes management in Mexico, highlighting the government’s recent commitment to tackle this public health issue and the company’s contribution to the dialogue. You were appointed as the director for public affairs two years ago, and recently of market…

regulatory Alejandro Luna and José Alfredo Sedano, lawyers at the leading legal firm of Santamarina y Steta, discuss the current legal challenges faced by companies in the pharmaceutical and healthcare sector in Mexico and urge for the amendment of the current regulatory framework. How was the healthcare and life science practice…